No Data
No Data
No Data
Not Many Are Piling Into Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Just Yet
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 31x, you may consider Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) as an attractive investment with
Red Sun Pharmaceutical (300026.SZ): Yao Xiaoqing resigns as chairman
Gelonghui, April 1, 丨 Hongri Pharmaceutical (300026.SZ) announced that the board of directors of the company recently received a written application for resignation from Mr. Yao Xiaoqing, the chairman of the company. Mr. Yao Xiaoqing applied to resign as the company's legal representative, chairman, director and relevant positions in the special committee of the board of directors due to personal work reasons. After his resignation, he no longer held any position in the company.
Hongri Pharmaceutical (300026.SZ): The subsidiary looks forward to the pharmaceutical industry selling esprolol hydrochloride raw materials
Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform. “Do your company and subsidiaries have esprolol hydrochloride APIs and corresponding formulations?” The company replied that the company's subsidiary expects the pharmaceutical industry to sell esprolol hydrochloride APIs.
Hongri Pharmaceutical (300026.SZ): Ketorolac tromethanol injection is currently under CDE review
Gelonghui, March 29丨An investor asked Hongri Pharmaceutical (300026.SZ) on the investor interactive platform, “The consistency evaluation of your company's ketorolac tromethotriol injection completed various technical reviews at the end of August 2023. Why hasn't it been approved until now?” The company replied that ketorolac and tromethotriol injections are currently under CDE review.
Red Sun Pharmaceutical (300026.SZ): Net profit for 2023 will drop 18.84% to 507 million yuan, and plans to distribute 10 to 0.3 yuan
Gelonghui March 28 | Hongri Pharmaceutical (300026.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 6.109 billion yuan, a year-on-year decrease of 8.14%; net profit attributable to shareholders of listed companies was 507 million yuan. , a year-on-year decrease of 18.84%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376 million yuan, a year-on-year decrease of 34.20%; basic earnings per share were 0.17 yuan; it is proposed to distribute a cash dividend of 0.30 yuan (tax included) for every 10 shares to all shareholders.
The One-year Shareholder Returns and Company Earnings Persist Lower as Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Stock Falls a Further 6.1% in Past Week
The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. That downside
No Data